GlassScriptPhysician profile
Prajwol Pathak
NPI 1366739575
$4,211.82
in general payments reported to CMS, 2019-2025
37 companies · $869 in 2025
The $869 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $60.07 · 2021: $11.92 · 2022: $356 · 2023: $1,506 · 2024: $1,409 · 2025: $869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,750 · Education: $34.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,750.04 |
| Education | $34.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $649.29 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $307.25 | 2022-2025 | Opdivo |
| Celgene Corporation | $302.93 | 2023-2025 | Reblozyl, Pomalyst, Opdualag |
| Janssen Biotech, INC. | $281.66 | 2023-2025 | Darzalex, Rybrevant, Tecvayli |
| Genzyme Corporation | $276.28 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $276.19 | 2022-2025 | Calquence, Imfinzi |
| Daiichi Sankyo INC. | $205.10 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Pfizer INC. | $178.65 | 2022-2024 | |
| Glaxosmithkline, LLC. | $172.28 | 2023-2025 | Ojjaara, Jemperli, Blenrep |
| Regeneron Healthcare Solutions, INC. | $157.59 | 2023-2025 | Libtayo |
| Incyte Corporation | $154.63 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Lilly USA, LLC | $153.16 | 2022-2024 | Verzenio, Jaypirca, Retevmo |
| Merck Sharp & Dohme LLC | $137.29 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Exelixis INC. | $102.22 | 2023-2025 | Cabometyx |
| Astellas Pharma US INC | $100.68 | 2023-2024 | Padcev, Xospata, Xtandi |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $84.75 | 2022-2023 | Vectibix, Nplate, Xgeva |
| Bayer Healthcare Pharmaceuticals INC. | $82.95 | 2022-2024 | |
| Genentech USA, INC. | $78.48 | 2022-2024 | Columvi, Polivy, Lunsumio |
| Pharmacosmos Therapeutics INC. | $75.84 | 2023-2024 | Monoferric, Cosela |
| Eisai INC. | $66.43 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.07 | 2020 | |
| Alexion Pharmaceuticals, INC. | $46.44 | 2023-2024 | Ultomiris, Soliris |
| Gilead Sciences, INC. | $31.03 | 2021-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $22.14 | 2025 | Fruzaqla |
| G1 Therapeutics, INC. | $19.51 | 2023 | Cosela |
| Ipsen Biopharmaceuticals, INC | $18.80 | 2023 | Somatuline Depot, Onivyde |
| Deciphera Pharmaceuticals INC. | $18.04 | 2025 | Qinlock, Romvimza |
| Adc Therapeutics America, INC. | $16.51 | 2023 | |
| Mirati Therapeutics, INC. | $16.47 | 2023 | Krazati |
| Kite Pharma, INC. | $16.28 | 2025 | Yescarta |
| Azurity Pharmaceuticals, INC. | $15.90 | 2025 | Danziten |
| Adaptive Biotechnologies Corporation | $15.60 | 2023 | Clonoseq |
| Beigene USA, INC. | $15.44 | 2023 | Brukinsa |
| Seagen INC. | $14.68 | 2023 | Tukysa |
| Rigel Pharmaceuticals, INC. | $14.35 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Puma Biotechnology, INC. | $13.72 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prajwol Pathak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.